Suppr超能文献

自身反应性心肌炎的免疫抑制治疗——一项对照试验的结果

Immunosuppressive treatment in autoreactive myocarditis--results from a controlled trial.

作者信息

Maisch B, Schönian U, Hengstenberg C, Herzum M, Hufnagel G, Bethge C, Bittinger A, Neumann K

机构信息

Philipps-University, Department of Internal Medicine-Cardiology, Marburg, Germany.

出版信息

Postgrad Med J. 1994;70 Suppl 1:S29-34.

PMID:7971646
Abstract

It is still a matter of controversy whether immunosuppressive therapy is beneficial in patients with acute myocarditis, although autoimmune mechanisms play an important role in the development of myocarditis and its sequelae, for example, in dilated heart muscle disease, particularly because it is postulated that in man immunosuppression may aggravate the viral cell damage that is proposed to trigger the myocarditis. We report the clinical (NYHA-class), haemodynamic (improvement of left ventricular ejection fraction, left ventricular end-diastolic volume index), histological (infiltrate, fibrosis, myocyte hypertrophy) and immunohistological (immunoglobulin and C3-binding) findings in a controlled study including 17 patients with active myocarditis or acute perimyocarditis who were treated with a combination of prednisone and azathioprine for 3 months. We compared them with 21 patients of comparable clinical and haemodynamic compromise who underwent conventional treatment. Follow-up examinations were performed after 3 months. There was significant improvement of ejection fraction and NYHA-classification under immunosuppressive treatment. Infiltrates were reduced significantly in the immunosuppressed patients group only. Binding of IgG and IgM in the endomyocardial biopsy was diminished slightly but not significantly by both regimens. Fibrosis and myocyte hypertrophy were augmented in both treatment arms. There was no difference with respect to prognosis: four patients died or underwent heart transplantation in the immunosuppressive treatment group compared to five conventionally treated patients.

摘要

免疫抑制疗法对急性心肌炎患者是否有益仍存在争议,尽管自身免疫机制在心肌炎及其后遗症(例如扩张型心肌病)的发展中起重要作用,特别是因为据推测,在人类中免疫抑制可能会加重被认为引发心肌炎的病毒对细胞的损伤。我们报告了一项对照研究的临床(纽约心脏协会分级)、血流动力学(左心室射血分数、左心室舒张末期容积指数的改善)、组织学(浸润、纤维化、心肌细胞肥大)和免疫组织学(免疫球蛋白和C3结合)结果,该研究纳入了17例活动性心肌炎或急性心包心肌炎患者,他们接受泼尼松和硫唑嘌呤联合治疗3个月。我们将他们与21例临床和血流动力学情况相当且接受传统治疗的患者进行了比较。3个月后进行了随访检查。免疫抑制治疗后射血分数和纽约心脏协会分级有显著改善。仅免疫抑制治疗组的浸润明显减少。两种治疗方案均使心内膜活检中IgG和IgM的结合略有减少,但不显著。两个治疗组的纤维化和心肌细胞肥大均加重。预后方面没有差异:免疫抑制治疗组有4例患者死亡或接受心脏移植,而传统治疗组有5例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验